News from Boehringer Ingelheim Vetmedica, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

30 Mar, 2017, 08:00 ET Novozymes and Boehringer Ingelheim announce Strategic Collaboration in Probiotics for Poultry Hatcheries

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global...


28 Mar, 2017, 08:00 ET Yankees Baseball Legend Bernie Williams Raises Awareness of Devastating Lung Disease - IPF - in Honor of his Dad

New York Yankees all-time great Bernie Williams is teaming up with Boehringer Ingelheim to raise awareness of a lung disease called idiopathic...


18 Jan, 2017, 09:00 ET Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by...


06 Dec, 2016, 06:42 ET Novo medicamento da Boehringer Ingelheim para câncer de pulmão bloqueia de forma irreversível a multiplicação das células cancerígenas

A Boehringer Ingelheim, uma das principais farmacêuticas do mundo focada em pesquisa para soluções terapêuticas inovadoras, lança no Brasil o...


26 Oct, 2016, 08:00 ET Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim today announced top-line results from the pivotal Phase III clinical study of BI 695501, a biosimilar candidate to...


24 Oct, 2016, 08:00 ET Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST

At CHEST 2016, two post-hoc pooled analyses of the Phase III INPULSIS® trials were presented that further demonstrate the efficacy of Ofev®...


09 Oct, 2016, 08:05 ET Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO

Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation...


28 Sep, 2016, 08:00 ET Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics

 Boehringer Ingelheim and ViraTherapeutics today announced a long-term collaboration to jointly develop a next generation oncolytic virus...


27 Sep, 2016, 08:30 ET Boehringer Ingelheim Named to the 2016 Working Mother 100 Best Companies List

Boehringer Ingelheim announced today that it has been named to Working Mother magazine's annual 100 Best Companies list for the fifth consecutive...


02 Jun, 2016, 08:00 ET Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

 Boehringer Ingelheim has initiated the ELUXA trial program, designed to further investigate the therapeutic potential of olmutinib (BI...


29 Feb, 2016, 15:25 ET Boehringer Ingelheim lança medicamento inédito para doença rara e revoluciona panorama de tratamento da Fibrose Pulmonar Idiopática

 A Boehringer Ingelheim, uma das 20 principais farmacêuticas do mundo, anuncia o lançamento de OFEV® (nintedanibe) no Brasil,...


21 Dec, 2015, 08:00 ET Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...


02 Dec, 2015, 08:00 ET Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...


02 Feb, 2015, 05:00 ET Leading Animal Health Company, Boehringer Ingelheim Vetmedica, Inc., Announces Website Redesign

Today, Boehringer Ingelheim Vetmedica, Inc. (BIVI), the 5th largest animal health company in the United States, announces the launch of its...


12 Jan, 2015, 08:00 ET The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy

 Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III...


03 Nov, 2014, 08:00 ET FDA Study of Medicare Patients Reaffirms Safety and Efficacy Profile of Pradaxa® (dabigatran etexilate mesylate) for NVAF

 A U.S. Food and Drug Administration (FDA) study of more than 134,000 Medicare patients found that Pradaxa® (dabigatran etexilate...


21 Oct, 2014, 08:00 ET Boehringer Ingelheim initiates global Phase III study investigating nintedanib in patients with colorectal cancer

 Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal...


20 Oct, 2014, 15:00 ET OFEV® (nintedanib) Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV® (nintedanib) capsules are now commercially available in the United...


26 Sep, 2014, 12:30 ET Boehringer Ingelheim Statement on FDA Drug Development Public Meeting for Idiopathic Pulmonary Fibrosis (IPF)

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting...


01 Aug, 2014, 08:05 ET FDA Approves Boehringer Ingelheim's Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi® Respimat® (olodaterol)...


23 Jul, 2014, 14:00 ET Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed

 Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ)...


08 Jul, 2014, 07:38 ET Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

 Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in...


28 May, 2014, 08:00 ET Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) Litigation

 Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation...


21 May, 2014, 11:15 ET Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD

 Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the...